KRYS vs VRTX
KRYS: Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical gene therapy for dystrophic epidermolysis bullosa. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | KRYS | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $336.80 | $472.57 | |
| Market cap as of 2026-07-23 | $9.9B | $121.4B | |
| P/E as of 2026-07-23 | 44.15 | 27.98 | VRTX lower |
| PEG as of 2026-07-23 | 0.72 | 2.31 | KRYS lower |
| Net margin as of 2026-07-23 | +53.9% | +35.5% | KRYS higher |
| Gross margin as of 2026-07-23 | +94.2% | +86.2% | KRYS higher |
| Operating margin as of 2026-07-23 | +42.8% | +38.3% | KRYS higher |
| ROE as of 2026-07-23 | +19.3% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | +17.6% | +17.2% | KRYS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | KRYS lower |
| Revenue growth (YoY) as of 2026-07-23 | +25.1% | +10.1% | KRYS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-07-23 | 0.54 | 0.30 | |
| 1-year return as of 2026-07-22 close | +121.7% | +0.5% | KRYS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.